

## Geriatric assessment in acute myeloid leukemia: current and future landscape

Kah Poh Loh<sup>1</sup> and Heidi D. Klepin<sup>2</sup>

<sup>1</sup>Division of Hematology/Oncology, James P. Wilmot Cancer Institute, University of Rochester/Strong Memorial Hospital, Rochester, NY; and <sup>2</sup>Section of Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC

The audio version of this Blood Advances Talk is available on the full-text article page.

## **Abstract**

Treatment of older adults with acute myeloid leukemia (AML) remains challenging despite advances in therapeutic options. Older adults of the same chronologic age can differ widely from one another based on underlying health status and physiologic reserve. Decision making and management cannot be optimized using strategies based on chronologic age. The heterogeneity of aging is not captured by performance status alone but requires additional evaluation of characteristics such as physical function, comorbidity, cognitive function, emotional health, and social support. Geriatric assessment is a multidimensional strategy used to provide a comprehensive evaluation of health status that can inform decision making and management for older adults with acute leukemia. This talk will provide an overview of available evidence addressing the role of geriatric assessment and highlight the next steps for a research agenda to support personalized care for older adults with AML from diagnosis through survivorship.

Download or subscribe to the *Blood Advances* Talk podcast at https://soundcloud.com/blood-advances.

The complete text of this *Blood Advances* Talk is available as a data supplement.

© 2018 by The American Society of Hematology

Contribution: K.P.L. and H.D.K. contributed to the concept, writing, editing, and final approval of the manuscript.

Conflict-of-interest disclosure: H.D.K. contributes to UpToDate on assessment strategies for older adults with AML and is an unpaid scientific consultant to Genentech on geriatric assessment in AML. K.P.L. declares no competing financial interests.

ORCID profiles: K.P.L., 0000-0002-6978-0418; H.D.K., 0000-0002-6262-1123. Correspondence: Heidi D. Klepin, Department of Internal Medicine, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157; e-mail: hklepin@wakehealth.edu.